MX2024002010A - Vacunas terapeuticas contra el virus del papiloma. - Google Patents
Vacunas terapeuticas contra el virus del papiloma.Info
- Publication number
- MX2024002010A MX2024002010A MX2024002010A MX2024002010A MX2024002010A MX 2024002010 A MX2024002010 A MX 2024002010A MX 2024002010 A MX2024002010 A MX 2024002010A MX 2024002010 A MX2024002010 A MX 2024002010A MX 2024002010 A MX2024002010 A MX 2024002010A
- Authority
- MX
- Mexico
- Prior art keywords
- therapeutic
- papilloma virus
- virus vaccines
- nucleic acid
- vaccines
- Prior art date
Links
- 229960002566 papillomavirus vaccine Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 241001631646 Papillomaviridae Species 0.000 abstract 1
- 108010076039 Polyproteins Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21191940.2A EP4137153A1 (en) | 2021-08-18 | 2021-08-18 | Therapeutic papilloma virus vaccines |
| PCT/EP2022/073016 WO2023021116A1 (en) | 2021-08-18 | 2022-08-17 | Therapeutic papilloma virus vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002010A true MX2024002010A (es) | 2024-04-18 |
Family
ID=77398487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002010A MX2024002010A (es) | 2021-08-18 | 2022-08-17 | Vacunas terapeuticas contra el virus del papiloma. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250066427A1 (https=) |
| EP (2) | EP4137153A1 (https=) |
| JP (1) | JP2024532853A (https=) |
| KR (1) | KR20240095168A (https=) |
| CN (1) | CN117940156A (https=) |
| AU (1) | AU2022331111A1 (https=) |
| CA (1) | CA3229203A1 (https=) |
| MX (1) | MX2024002010A (https=) |
| WO (1) | WO2023021116A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4720309A1 (en) * | 2023-05-26 | 2026-04-08 | ProBioGen AG | Diploid recombinant nucleocytoplasmic large dna viral vectors |
| CN120607593A (zh) * | 2024-03-06 | 2025-09-09 | 诺未生物技术(无锡)有限公司 | 治疗hpv感染相关疾病的药物 |
| CN119569831B (zh) * | 2024-12-13 | 2026-04-28 | 深圳锦时生物科技有限公司 | 一种活性多肽及在预防和/或治疗hpv中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2457890A1 (en) * | 2001-08-23 | 2003-03-06 | Merck & Co., Inc. | Vaccine using papillomavirus e proteins delivered by viral vector |
| EP1957528B1 (en) | 2005-11-30 | 2012-11-07 | University of Copenhagen | A nucleotide vaccine |
| EP3552622A3 (en) | 2008-11-21 | 2019-12-04 | Københavns Universitet (University Of Copenhagen) | Priming of an immune response |
| GB201321384D0 (en) | 2013-12-04 | 2014-01-15 | Isis Innovation | Molecular adjuvant |
| GB201704417D0 (en) | 2017-03-20 | 2017-05-03 | Univ Copenhagen | Improved li vaccine adjuvant |
| US12576143B2 (en) | 2018-10-19 | 2026-03-17 | Nouscom Ag | Teleost invariant chain cancer vaccine |
-
2021
- 2021-08-18 EP EP21191940.2A patent/EP4137153A1/en not_active Withdrawn
-
2022
- 2022-08-17 JP JP2024510296A patent/JP2024532853A/ja active Pending
- 2022-08-17 CA CA3229203A patent/CA3229203A1/en active Pending
- 2022-08-17 AU AU2022331111A patent/AU2022331111A1/en active Pending
- 2022-08-17 MX MX2024002010A patent/MX2024002010A/es unknown
- 2022-08-17 EP EP22768288.7A patent/EP4387662A1/en active Pending
- 2022-08-17 KR KR1020247008839A patent/KR20240095168A/ko active Pending
- 2022-08-17 US US18/684,381 patent/US20250066427A1/en active Pending
- 2022-08-17 WO PCT/EP2022/073016 patent/WO2023021116A1/en not_active Ceased
- 2022-08-17 CN CN202280053653.9A patent/CN117940156A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023021116A1 (en) | 2023-02-23 |
| EP4137153A1 (en) | 2023-02-22 |
| CA3229203A1 (en) | 2023-02-23 |
| EP4387662A1 (en) | 2024-06-26 |
| JP2024532853A (ja) | 2024-09-10 |
| CN117940156A (zh) | 2024-04-26 |
| KR20240095168A (ko) | 2024-06-25 |
| US20250066427A1 (en) | 2025-02-27 |
| AU2022331111A1 (en) | 2024-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024002010A (es) | Vacunas terapeuticas contra el virus del papiloma. | |
| AR077396A2 (es) | EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS | |
| PE20190433A1 (es) | Vacuna contra vrs | |
| CL2024001737A1 (es) | Variantes de nucleasas cas12a y métodos de preparación y uso de las mismas | |
| GEAP202416053A (en) | Modified short interfering nucleic acid (sina) molecules and uses thereof | |
| EA201891415A8 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения | |
| CL2017001089A1 (es) | Vacunas terapéuticas contra el vph16 | |
| CO6480995A2 (es) | Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv | |
| CR20170350A (es) | Dinucleótidos cíclicos útiles en el tratamiento del cáncer | |
| BR112018008090A2 (pt) | vacina de vírus do herpes simplex. | |
| MX2019004913A (es) | Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm). | |
| EA201891000A1 (ru) | Вакцина против респираторно-синцитиального вируса | |
| MX2020001655A (es) | Vacuna vph. | |
| PE20160045A1 (es) | Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados | |
| UY33297A (es) | Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas | |
| AR039005A1 (es) | Antigenos virales | |
| CY1111378T1 (el) | Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna | |
| BRPI0913012A2 (pt) | vírus do nilo ocidental/da dengue quiméricos | |
| EA201990071A1 (ru) | Композиция пептидной вакцины | |
| MX2021007241A (es) | Acido ribonucleico (arn) que codifica para una proteina. | |
| EA201170965A1 (ru) | Усовершенствованные вакцины вируса человеческой папилломы и способы их использования | |
| CL2019000640A1 (es) | Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso. | |
| AR071220A1 (es) | Astrovirus aviario depositado bajo el nuero cncm i-3895 | |
| CO2019009815A2 (es) | Combinaciones farmacéuticas | |
| EA202092990A2 (ru) | Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу |